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Introduction
In 2010, it is estimated that more than 200,000 women 
will be newly diagnosed with invasive breast cancer in 
the United States [1], making it the most commonly 
diagnosed cancer in women. Th   e majority of women are 
post-menopausal at the time of diagnosis. Adjuvant 
endocrine manipulations reduce the risk of breast 
cancer-related recurrence and death in women with 
hormone receptor-positive disease. Th  e introduction of 
aromatase inhibitors (AIs) to the adjuvant treatment of 
postmenopausal women with hormone receptor-positive 
breast cancer has signiﬁ  cantly changed the management 
of the disease. Th   ese agents are commonly used instead 
of or in sequence with tamoxifen because of the 
demonstrated improvement in disease-free survival 
compared to tamoxifen alone [2]. Since long-term sur-
vival rates are high in patients with early-stage breast 
cancer who receive AIs and treatment may continue for 
many years, the complications arising from therapy in 
this patient population can have long-term eﬀ  ects and 
may greatly impact patient quality of life.
Th   e three third-generation AIs in routine clinical use - 
anastrozole (Arimidex), letrozole (Femara), and exemes-
tane (Aromasin) - have similar eﬃ   cacy  and  toxicity 
proﬁ  les when evaluated in cross-study comparisons. Th  e 
primary adverse eﬀ  ects include menopausal symptoms, 
vaginal dryness, sexual dysfunction, and musculoskeletal 
symptoms, including bone demineralization with risk of 
osteoporosis and fracture, arthralgias, and myalgias. Th  is 
review will focus on AI-associated bone and musculo-
skeletal toxicities, including prevalence, typical symp-
toms, potential etiologies, and strategies for management 
of these side eﬀ  ects.
Aromatase inhibitor effi   cacy and safety
Estrogen is primarily produced in the ovary prior to 
menopause. After menopause, estrogen production occurs 
in peripheral tissues (skin, muscle, fat, and benign and 
malignant breast tissue) through the conversion of 
androgens to estrogens by the P450 cytochrome enzyme 
aromatase (CYP19) [3-6]. Th   ere are two primary 
approaches to the hormonal treatment of estrogen 
receptor (ER)-positive breast cancers: selective ER modu-
lators (for example, tamoxifen) that directly interact with 
the ER and inhibit its activity in breast tissue; and AIs 
that reduce post-menopausal production of estrogen [2]. 
Th   e nonsteroidal AIs anastrozole and letrozole competi-
tively inhibit aromatase, while the steroidal AI exemes-
tane irreversibly inhibits the enzyme; however, both 
types of inhibitors suppress plasma and tissue estrone 
concentrations, the dominant estrogen in post-meno-
pausal women, by >93% [7-9]. AIs are ineﬀ  ec  tive  in 
women with functional ovaries because of their inability 
to block ovarian production of estrogen [10].
Numerous large randomized controlled trials have 
evaluated AIs in the treatment of early-stage hormone 
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consistently demonstrated improved disease-free survival 
when used in multiple settings: upfront in place of 
tamoxifen, following 2 to 3 years of tamoxifen (sequential 
strategy), or after completion of 5 years of tamoxifen 
therapy (extended strategy) [11-19]. However, there has 
been no overall survival advantage when compared to 
tamoxifen.
Results of these clinical trials have also demonstrated a 
favorable safety proﬁ   le for the AIs compared to 
tamoxifen. In the long-term safety analysis of the Anas-
trozole, Tamoxifen Alone or in Combination (ATAC) 
trial, signiﬁ  cantly fewer treatment-related adverse events 
were observed resulting in fewer withdrawals due to 
drug-related adverse events in the anastrozole group 
compared to tamoxifen alone. In comparison to tamoxi-
fen, anastrozole was associated with fewer thrombo-
embolic events, cerebrovascular events, and diagnoses of 
endometrial cancer [11]. However, reports of osteopenia, 
osteoporosis, and fracture rates were increased in the 
anastrozole group as were rates of dyspareunia and 
decreased libido secondary to vaginal dryness, increased 
lipidemia, and worsening joint symptoms. Similar results 
were seen in the major trials of each of the third 
generation AIs [11-18,20].
Bone demineralization and aromatase inhibitors
Numerous reports have demonstrated that aromatase 
sup  pression leads to clinically signiﬁ  cant  bone 
de  minerali  zation resulting in increased rates of 
osteopenia, osteoporosis, and fractures (Table 1). In the 
ATAC study, higher fracture rates were reported in the 
anastrozole arm when compared to tamoxifen (2.93% 
versus 1.9%, respectively, P < 0.0001, after a median 
follow-up of 100 months) [21]. However, after treatment 
was completed, fracture rates were equivalent. Th  e 
fracture rate in anastrozole-treated women appeared to 
plateau after 24 months, with no progressive increase in 
fracture risk, although the fracture risk remained 
signiﬁ  cant [22]. In the Breast International Group (BIG) 
1-98 trial, which directly compared 5 years of adjuvant 
tamoxifen with 5 years of letrozole, the fracture rate was 
signiﬁ  cantly higher in the letrozole group (8.6% versus 
5.8%,  P < 0.001) at 60 months follow-up [13]. Th  e 
Intergroup Exemestane Study is a sequential dosing study 
designed to compare 5 years of tamoxifen with 2 to 3 years 
of tamoxifen followed by 2 to 3 years of exemestane [23]. 
After a median follow-up of 55.7 months, fracture rates 
and new diagnoses of osteoporosis were increased in 
patients receiving exemestane versus tamoxifen alone 
(4.3% versus 3.1%, respectively, for fractures, P = 0.03; 
and 7.3% versus 5.5%, respectively, for osteoporosis, 
P  =  0.01) [14]. In each of these studies, the AI was 
compared to tamoxifen, which is thought to have a weak 
estrogenic eﬀ  ect on bone tissue, reducing bone resorp-
tion and maintaining bone mineral density [24,25]. Th  e 
diﬀ  erence in fracture rates becomes less apparent when 
compared to placebo. In the National Cancer Institute of 
Table 1. Incidence of bone fractures and osteoporosis in patients treated with aromatase inhibitors versus tamoxifen or 
placebo in randomized phase III trials
  Treatment arms    Aromatase  Tamoxifen/  
Study  (years of treatment)  Symptom  inhibitor (%)  placebo (%)  P-value
ATAC [11,21]  Anastrozole (5)  Fractures  2.93  1.9  <0.0001
  versus  Osteopenia or osteoporosis  11  7  <0.0001
 Tamoxifen  (5) 
ABCSG8/ ARNO95 [16]  Tamoxifen (2-3)  Anastrozole (3)  Fractures  2  1  0.015
 versus
 Tamoxifen  (5)
ABCSG6a [17]  Tamoxifen (5)  Anastrozole (3)  Fractures  0.8  1.1  NA
 versus
 Tamoxifen  (5)   Placebo (3)
BIG 1-98 [13]  Letrozole (5)  Fractures  8.6  5.8  <0.001
 versus
 Tamoxifen  (5)
IES [14]  Tamoxifen (2-3)  Exemestane (2-3)  Fracturea 4.3  3.1  0.03
 versus  Osteoporosis  7.3  5.5  0.01
 Tamoxifen  (5)
MA.17 [15]  Tamoxifen (5)  Letrozole (5)  Fracture  5.3  4.6  0.25
 versus  Osteoporosis  8.1  6  0.003
 Tamoxifen  (5)   Placebo (5)
aFracture risk increased with exemestane versus tamoxifen (7 versus 4.9, respectively; P-value 0.003) after completion of therapy. ABCSG, Austrian Breast and 
Colorectal Cancer Study Group; ARNO, Arimidex-Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in Combination; BIG, Breast International Group; IES, International 
Exemestane Study; NA, not available.
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5 years of letrozole were compared to placebo in women 
who completed 5 years of tamoxifen, there was no 
diﬀ   erence in the incidence of clinical fractures in the 
letrozole group compared with the placebo group (5.3% 
versus 4.6%, P = 0.25); however, more women receiving 
letrozole reported new diagnosis of osteoporosis in the 
2 years following initiation of therapy (8.1% versus 6%, 
P = 0.003) [15]. Overall, fracture and osteoporosis rates 
were increased regardless of which AI or dosing strategy 
was used.
Bone mineral density as a marker of AI-induced bone 
fragility
In a substudy of the ATAC trial, there was a signiﬁ  cant 
reduction in lumbar spine and hip bone mineral density 
(BMD; 2.2% and 1.3%, respectively) in patients receiving 
anastrozole over the ﬁ  rst year of treatment; while BMD 
signiﬁ  cantly increased in women treated with tamoxifen 
over the same time period (1.0% and 0.5% increase in 
lumbar spine and hip, respectively) [26]. Over the 5 years 
of the study, the median decrease in lumbar spine BMD 
was -6.08% in the anastrozole-treated group compared 
with an increase of +2.77% in the tamoxifen-treated 
group [27]. Similar results were seen in the total hip 
measurements (-7.24% and +0.74% in the anastrozole and 
tamoxifen groups, respectively). After 2 years, patients in 
the MA.17 bone subprotocol receiving letrozole had a 
signiﬁ   cant decrease in total hip (-3.6% versus -0.71%, 
P = 0.044) and lumbar spine BMD (-5.35 versus -0.7%, 
P = 0.008) compared with placebo [28]. Whether BMD 
can be used as a surrogate for fragility fracture risk is 
controversial [29].
Proposed mechanism of bone loss
Bone metabolism is a balance between osteoblastic and 
osteoclastic activity. Estrogen deﬁ  ciency has been identi-
ﬁ  ed as the key factor in mediating age-related bone loss 
[30]. Th  ere is a clear association between post-meno-
pausal estrogen deﬁ   ciency and the development of 
osteoporosis. ERs and aromatase are both expressed in 
bone, and estrogen has been shown to regulate bone 
remodeling by stimulating the expression of anti-
resorptive factors such as osteoprotegerin. Th   is results in 
the attenuation of receptor activator of NF-kappa-B 
(RANK) and RANK ligand (RANKL) signaling, leading 
to inhibition of osteoclastogenesis and attenuated bone 
turnover [31,32]. Indeed, estrogen deﬁ   ciency is asso-
ciated with increased expression of measurable markers 
of bone resorption and bone formation [33].
Molecular markers of bone turnover in AI-treated patients
Markers of bone remodeling were evaluated in several 
studies and the results support AI-associated increase in 
bone remodeling. In the ATAC bone substudy, at one 
year patients receiving anastrozole had a signiﬁ  cant 
increase in markers of bone resorption, including C-
telopeptide (CTX; +26%) and N-telopeptide (NTX; 
+15%) along with an increase in markers of bone 
formation, including bone alkaline phosphatase (ALP; 
+20%) and procollagen type-I N-propeptide (PINP; 
+18%) [26]. In contrast, patients receiving tamoxifen had 
a decrease in both resorption and formation markers 
(CTX -56%, NTX -52%, ALP -16%, PINP -72%). In the 
MA.17 bone substudy, an increase in the bone resorption 
markers NTX and CTX were observed in patients treated 
with letrozole at 24 months (+57% and +17%, 
respectively, compared to +16% and -12%, respectively, in 
patients treated with tamoxifen) [28]. In a double-blind 
placebo-controlled study comparing bone turnover 
markers following 2 years of exemestane to placebo in 
women with early breast cancer, exemestane was 
associated with a signiﬁ   cant increase in the markers 
compared to placebo (ALP +52% and +25%, respectively, 
and CTX +35% and -5%, respectively) [34].
Together, the data demonstrate that all AIs have 
potentially deleterious eﬀ  ects on measures of bone health 
with a decrease in BMD and increase in bone-re-
modeling. However, the overall incidence of fractures 
during 5 years of AI therapy is quite low. In the Anas-
trozole versus Letrozole, an Investigation of Quality Of 
Life and Tolerability (ALIQUOT) study, both anastrozole 
and letrozole were associated with similar eﬀ  ects on bone 
metabolism and turnover in postmenopausal women 
with ER-positive breast cancer [35]. In this study, 
discontinuing tamoxifen therapy and initiating an AI was 
associated with an increased rate of turnover compared 
to starting an AI in a patient who had never received 
tamoxifen. At the same time, the administration of 
tamoxifen after AI therapy is associated with a decrease 
in markers of bone resorption.
Risk factors
In the bone substudy of the BIG1-98 trial, several risk 
factors for the development of fractures were identiﬁ  ed, 
including increased age, prior fractures, diagnosis of 
osteoporosis at baseline, and previous hormone therapy 
[36]. Similarly, another study identiﬁ  ed eight risk factors 
among women with breast cancer: AI therapy, T-score 
<-1.5, age >65 years, low body mass index (<20 kg/m2), 
family history of hip fracture, personal history of fragility 
fracture after age 50 years, oral corticosteroid use 
>6 months, and smoking [37]. Bone mineral loss was also 
increased in women who received letrozole in the 4 years 
since menopause compared to women who were more 
than 4 years since their menopause (median percent 
change -11.32 in women <4 years from last menstrual 
period and -5.41 in women >4 years since last menstrual 
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consideration in assessing the most appropriate adjuvant 
therapy with the least toxicity for an individual woman.
Guidelines for management of AI-associated bone loss
Given the risk of developing skeletal-related events in 
otherwise healthy women with early-stage breast cancer 
treated with AIs, there has been a signiﬁ  cant interest in 
determining the best preventative measures and treat-
ment strategies. Recent guidelines have been published 
with recommendations for the management of AI-
induced bone loss [2,37,38]. As in all postmenopausal 
women, adequate dietary vitamin D and calcium intake 
are important for maintaining BMD [39]. Resistance and 
aerobic exercise also slows BMD loss in women with 
early breast cancer receiving cytotoxic chemotherapy 
[40]; however, the eﬀ  ects on AI-associated BMD are un-
known. Reduction of other risk factors, such as cessation 
of smoking and minimization of other drugs associated 
with decreasing BMD (for example, corticosteroids), are 
also likely to have a positive impact on bone health. Dual 
energy X-ray absorptiometry (DEXA) scan to assess 
BMD is recommended at the initiation of therapy and at 
least every 2 years while receiving an AI [37].
Th  e American Society of Clinical Oncology (ASCO) 
guidelines on the management of bone health issues in 
women with breast cancer recommend initiation of 
bisphosphonate therapy if osteoporosis is present on 
DEXA scan (T-score <2.5) [41]. Th  e UK guidelines 
recom  mend more aggressive treatment of bone mineral 
loss. Bisphosphonate therapy is recommended in all 
elderly (>75 years of age) women with one or more risk 
factors for osteoporotic fracture irrespective of BMD 
[38]. Bisphosphonate therapy should be considered for 
any post-menopausal woman whose T-score falls below 
-2 or if the rate of bone loss in a woman with pre-existing 
osteopenia exceeds 4% per year. In premenopausal 
women receiving ovarian suppression and an AI, the 
threshold for intervention is a T-score <-1 (because of 
very rapid bone loss averaging 17% over 3 years) [42].
Which bisphosphonate to use in the treatment of AI-
associated bone loss has not been determined. Studies 
have demonstrated that intravenous zoledronic acid, oral 
ibandronate, and oral risedronate increase bone mineral 
density in AI-treated patients [42-47]. Another un-
answered question is whether bisphosphonates should be 
initiated at the start of AI therapy rather than delaying 
until osteoporosis develops. Th  e  Zometa-Femara 
Adjuvant Synergy (Z-FAST and ZO-FAST) trials were 
designed to evaluate an immediate versus delayed 
strategy of bone protection with zoledronic acid [43,44]. 
Immediate therapy was more eﬀ   ective in preserving 
BMD at 12 months than delaying bisphosphonate therapy 
until the lumbar spine or total hip T-score was below -2.0 
or when a non-traumatic fracture occurred. Neither 
study was powered to show a diﬀ  erence in the number of 
fractures. In the ARIBON trial (Arimidex-Bondronate), 
all patients received anastrozole but osteopenic patients 
were randomized at the start of therapy to receive either 
oral ibandronate or placebo. Patients receiving iban  dro-
nate gained rather than lost BMD (lumbar spine: +2.98% 
compared to -3.22% in patients receiving placebo) [45]. 
Similar results were found in the Study of Anastrozole 
with the Bisphosphonate Risedronate (SABRE) [46] and 
Arimidex Bone Mass Index and Oral Bisphosphonates 
(ARBI) [47] trials, showing the BMD loss can eﬀ  ectively be 
reduced or even completely mitigated by the addition of a 
bisphosphonate. However, whether the increase in bone 
mineral density and decrease in bone turnover translates 
into reduced fracture risk is under debate. Recent meta-
analyses of the bisphosphonates in AI patients have called 
their use into question, particularly for prevention of BMD 
loss. While bisphosphonates were associated with im-
proved BMD, there was no eﬀ  ect on fracture risk [48,49].
In addition to bisphosphonates, other treatment 
options are emerging. Denosumab, a RANKL targeted 
antibody that prevents bone resorption, was shown to 
increase BMD in AI-treated patients [50]. Combination 
therapy of AIs with inhibitors of Src, a non-receptor 
tyrosine kinase with roles in growth, metastasis, and 
bone metabolism, have shown promise in restoring 
sensitivity to endocrine-resistant cells [51]. Th  e  eﬀ  ects of 
this combination, and in particular evaluation of the 
eﬀ   ect on markers of bone resorption, are under 
evaluation in phase II clinical trials.
Aromatase inhibitor-induced arthralgias
Musculoskeletal symptoms have arisen as important 
adverse eﬀ  ects of AIs. In the major phase III clinical trials 
that compared AI to tamoxifen, the reported incidence of 
musculoskeletal symptoms ranged from 5 to 36% 
[11-18,20] (Table 2). However, case series have reported 
an even higher incidence of emergence of new or 
worsening joint symptoms in up to 61% of AI-treated 
women [52-55]. By contrast, tamoxifen has not been 
associated with increased joint symptoms [56,57]. While 
AI-induced arthralgias were reported as mild to 
moderate in severity and did not result in signiﬁ  cant 
discontinuation of medication in the large trials [58,59], 
in more recent analyses, severe AI-induced arthralgias 
resulted in therapy interruption in up to 20% of patients 
[52,55,60]. Th   erefore, AI-associated arthralgia may 
account for reduced medication compliance, leading to 
decreased eﬃ   cacy and an increase in recurrence rates. 
Despite the frequent reporting of AI-induced arthralgias, 
the etiology of this adverse eﬀ  ect remains unknown.
Th   e most commonly reported symptoms include 
morning stiﬀ  ness and pain of the hands, knees, hips, 
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perform activities of daily living as well as work-related 
tasks [53,61]. In a cross-sectional analysis of post-
menopausal women treated with adjuvant AI therapy at a 
university-based oncology clinic, the most common sites 
of joint pain were wrist/hand (60.4%), knee (59.7%), back 
(54%), ankle/foot (51.8%), and hip (42.5%) [62]. Digital 
stiﬀ  ness, trigger ﬁ  nger, and carpal tunnel syndrome have 
been frequently reported clinical symptoms [11,55,61,63]. 
Surgery for carpal tunnel syndrome was found to be up 
to seven times more frequent in patients receiving an AI 
than those receiving tamoxifen [11,64]. In initial studies 
exemestane was associated with dramatically increased 
risk of carpal tunnel syndrome compared to tamoxifen 
(2.8% versus 0.3%, respectively). In a 100-month follow-
up of the ATAC trial, symptoms were typically reported 
within the ﬁ  rst few months of therapy, to be of mild to 
moderate intensity, and of short duration [65]. Th  ere  was 
increased reporting of carpal tunnel symptoms, although 
the incidence remained low (2.6%) and generally did not 
require surgical intervention. In a prospective evaluation 
of 92 postmenopausal patients with early stage breast 
cancer taking adjuvant AIs, 32% of patients reported new 
or worsening arthralgia most commonly aﬀ  ecting  the 
knees (70%), wrists (70%), and small joints of the hands 
(63%) [66]. Most patients reported mild to moderate 
symptoms that were easily managed with analgesics and 
very few patients discontinued therapy due to emergence 
of symptoms. In contrast, in a small prospective study of 
25 patients, 15 patients developed AI-induced arthralgia 
within the ﬁ  rst 12 months of treatment and 13 patients 
discontinued therapy as a result of the musculoskeletal 
symptoms [67].
Etiology of aromatase inhibitor-induced arthralgias
Estrogen deprivation
Post-menopausal status and estrogen deﬁ  ciency  are 
associated with the development of joint pain and joint 
Table 2. Incidence of musculoskeletal symptoms in patients treated with aromatase inhibitors versus tamoxifen or 
placebo in randomized phase III trials
  Treatment arms    Aromatase  Tamoxifen/  
Study  (years of treatment)  Symptom  inhibitor (%)  placebo (%)  P-value
ATAC [11,12]  Anastrozole (5)  Arthralgia  35.6  29.4  <0.0001
  versus  Carpal tunnel syndrome  3  1  <0.0001
 Tamoxifen  (5)
ABCSG8/ ARNO95 [16]  Tamoxifen (2-3)  Anastrozole (3)  Bone pain  19  16  0.0546
 versus
 Tamoxifen  (5)
ABCSG6a [17]  Tamoxifen (5)  Anastrozole (3)  Bone pain including joint pain  24.5  18.3  0.009
 versus
 Tamoxifen  (5)   Placebo (3)
ITA [20]  Tamoxifen (2-3)  Anastrozole (2-3)  MSK disorders and bone fractures  9.9  6.7  0.2
 versus
 Tamoxifen  (5)
BIG 1-98 [13]  Letrozole (5)  Arthralgia  20.0  13.5  <0.001
 versus  Myalgia  7.1  6.1  0.19
 Tamoxifen  (5)
IES [14]  Tamoxifen (2-3)  Exemestane (2-3)  Arthritis  14.1  12.0  0.03
 versus  Arthralgia  18.6  11.8  <0.0001
  Tamoxifen (5)  Carpal tunnel syndrome  2.8  0.3  <0.0001
   MSK  pain  21  16.1  <0.0001
   Cramps  2.3  4.2  0.0002
   Joint  stiff  ness  1.9  1  0.009
NSABP B33 [18]  Tamoxifen (5)  Exemestane (5)  Arthralgia  1  0.5  NA
 versus
 Tamoxifen  (5)   Placebo (5)
MA17 [15]  Tamoxifen (5)  Letrozole (5)  Arthritis  6  5  0.07
 versus  Arthralgia  25  21  <0.001
 Tamoxifen  (5)   Placebo (5)  Myalgia  15  12  0.004
    Bone pain   5  6  0.67
ABCSG, Austrian Breast and Colorectal Cancer Study Group; ARNO, Arimidex-Nolvadex; ATAC, Arimidex, Tamoxifen, Alone or in Combination; BIG, Breast International 
Group; DFS, disease-free survival; IES, International Exemestane Study; ITA, Italian Trial of Anastrozole; MSK, musculoskeletal; NA, not available; NSABP, National 
Surgical Adjuvant Breast and Bowel Project.
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men  tation [68]. Estrogen deprivation has been hypothe-
sized as the major cause of AI-induced arthralgias. 
Indeed, development of arthralgia has also been seen in 
patients treated with the gonadotropin-releasing agonist 
leuprolide, which results in menopausal range estrogen 
concentrations [69]. Approximately 25% of women 
developed arthralgia within 3 weeks of initiation of 
leuprolide. Alternatively, estrogen-based therapy is asso-
ciated with reduced incidence of radiologic knee osteo-
arthritis and decreased incidence of joint pain/swelling 
[70-72]. However, this eﬀ  ect has not been seen in all 
studies of estrogen therapy [73]. Whether the eﬀ  ect is 
secondary to systemic or localized estrogen deﬁ  ciency is 
unclear. ERs have been identiﬁ   ed in cartilage and 
estrogen deﬁ   ciency in ovariectomized rats accelerated 
cartilage turnover and increased cartilage surface erosion 
while administration of estrogen suppressed cartilage 
degradation signiﬁ  cantly [74-78]. Surgically ovariectom-
ized primates similarly develop osteoarthritic changes 
that can be prevented by estrogen therapy [79]. Estrogen 
is associated with chondroprotective eﬀ  ects by decreas-
ing collagen degradation [80,81]. In addition, aromatase 
is expressed in synovial cells and chrondrocytes of 
articular cartilage with evidence of local conversion of 
androstenedione to estrone and estradiol [82,83]. 
Th   erefore, both systemic and local AI-induced estrogenic 
deﬁ  ciency may impair cartilage maintenance.
Anti-nociceptive eff  ects
Estrogen has also been associated with anti-nociceptive 
eﬀ  ects and it has been postulated that estrogen deﬁ  ciency 
results in increased sensation of pain [84]. Th  is 
hypothesis mainly stems from the observation that pain 
thresholds are aﬀ   ected by various hormonal states 
(increased pain thresholds during pregnancy) [85]. Th  is 
estrogen-dependent eﬀ  ect is mediated through the spinal 
cord kappa-opioid analgesic system. Th  e absence of 
estrogens thus would be expected to result in a reduction 
in analgesic eﬀ  ect [86]. ERs and aromatase are expressed 
in the central nervous system and local estrogen produc-
tion may modulate pain and sensory perception [87]. In 
contrast, several studies have reported that pain 
thresholds are actually decreased when estrogen levels 
are high [88,89]. Given the radiologic ﬁ  ndings associated 
with AI-induced arthralgia (see below), this eﬀ  ect is not 
likely solely related to pain perception.
Tenosynovial changes and joint eff  usions
Several studies have recently identiﬁ  ed  characteristic 
radiologic changes associated with AI-induced arthralgia. 
In a small study that evaluated 12 patients with severe 
AI-associated arthralgia, ultrasound evaluations revealed 
ﬂ  uid in the tendon sheath surrounding the digital ﬂ  exor 
tendons and MRI showed increased intra-articular ﬂ  uid 
as well as enhancement and thickening of the tendon 
sheath in all 12 patients [61]. In a larger prospective trial, 
patients who developed AI-related arthralgia were 
evaluated with musculoskeletal sonography and electro-
myo  graphy [66]. Patients with AI-induced arthralgia had 
higher rates of joint eﬀ  usions and more electromyography 
ﬁ   ndings consistent with carpal tunnel syndrome. 
Interestingly, a retrospective analysis of women treated 
with adjuvant AI therapy showed that women who were 
on chronic diuretic treatment for heart disease or hyper-
tension were less likely to have symptoms of arthralgia, 
muscular or skeletal stiﬀ   ness (6.97% versus 15.85%, 
P  =  0.01), suggesting that ﬂ  uid retention within joints 
may play a role in AI-induced arthralgia [90].
Autoimmunity
Another possible etiology involved a potential link 
between AI therapy and autoimmunity. In one study, 24 
women who developed disabling joint pain were referred 
for rheumatological consultation, radiological evaluation, 
and immunologic investigations [91]. Nineteen of the 24 
patients were found to have inﬂ   ammatory pain of 
multiple joints. Nine of the 19 had elevated antinuclear 
antibodies, four had increased rheumatoid factor serum 
concentrations, and two had laboratory abnormalities 
consistent with a systemic inﬂ  ammatory syndrome. Ten 
patients had symptoms consistent with sicca syndrome, 
and one met diagnostic criteria for Sjogren’s syndrome. 
In support of a possible autoimmune mechanism, there 
appears to be an association between estrogen deﬁ  ciency 
and increased secretion of proinﬂ  ammatory  cytokines 
[92]. Estrogens have also been shown to have signiﬁ  cant 
anti-inﬂ  ammatory properties by repressing the trans  crip-
tion of proinﬂ  ammatory genes through the ER [93]. In a 
prospective randomized study designated Exemestane 
and Letrozole Pharmacogenetics (ELPh), patients who 
developed worsening joint symptoms were referred for 
rheumatologic evaluation [55]. Only a small fraction of 
the participants had elevated concentrations of inﬂ  am-
matory or rheumatologic markers (5 to 18%). Th  ey  were 
most likely to be diagnosed with a moderate intensity, 
non-inﬂ   ammatory regional musculoskeletal disorder, 
including tendonitis/tenosynovitis (37%), osteoarthritis 
(29%), and carpal tunnel syndrome (21%). In a small 
cohort of the ELPh study, evaluation of concentrations 
of circulating inﬂ   ammatory markers in patients with 
AI-induced arthralgia showed no signiﬁ  cant change in 
the tested markers relative to pre-treatment concen-
trations or compared to women who did not report 
symptoms [94]. Although a small preliminary study, it 
supports other reports that AI-induced arthralgia is 
probably not associated with a systemic inﬂ  ammatory 
response.
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arthralgia
Several studies have evaluated the risk factors associated 
with AI-induced arthralgia. Overweight patients and 
those who had previously been treated with tamoxifen 
were at lower risk for AI-induced arthralgia, while 
patients who had previously been treated with taxanes 
were four times more likely to develop the symptoms 
[54]. In a separate study, interval since menopause was 
the only signiﬁ  cant risk factor (possibly linked to cyto-
kine activity or to a more precipitous drop in estrogen 
levels), with women who had their last menstrual period 
within 5 years of starting therapy more likely to develop 
joint symptoms compared to those whose last menstrual 
period was 10 years prior to starting therapy (73% versus 
35%, adjusted odds radio, 3.39; 95% conﬁ  dence interval, 
1.21 to 9.44; P = 0.02) [62]. Th   e majority of patients (75%) 
developed symptoms within 3 months of starting therapy. 
In a prospective evaluation of musculoskeletal symptoms 
that develop in women treated with AI, the median time 
to onset of symptoms was 1.6 months and 13% of patients 
discontinued AI therapy after a median of 6.1 months 
secondary to musculoskeletal toxicity [55]. Type of 
surgery, radiation therapy, chemotherapy, or tamoxifen use 
did not predict the development of symptoms, although 
the report focused on the ﬁ  rst 100 participants only.
A retrospective analysis of the ATAC trial identiﬁ  ed 
several risk factors for the development of arthralgia: 
previous hormone therapy, hormone receptor positivity, 
previous chemotherapy, obesity, and treatment with 
anastrozole. Only women without baseline joint symp  toms 
at the outset of the trail were included in the analysis; thus, 
the study does not evaluate risk factors associated with 
worsening joint symptoms in patients with baseline 
arthralgia [58]. Th   is study reports that women with joint 
symptoms at the outset reported fewer symptoms during 
treatment, which is in contrast to other studies.
In a retrospective analysis from the ATAC trial, 
treatment-induced vasomotor or joint symptoms were 
associated with improved eﬃ     cacy of the treatment, 
suggesting that adequate management of the symptoms 
is particularly important in maintaining medication com-
pliance [95]. Women who experienced joint symptoms 
(with or without vasomotor symptoms) after 3 months of 
endocrine therapy (anastrozole or tamoxifen) had a 
signiﬁ  cantly reduced risk of developing recurrent disease 
than those without joint symptoms (adjusted hazard ratio 
0.60 (0.50 to 0.72) P < 0.0001). While other preliminary 
investigation failed to show an association between AI-
related symptoms and outcomes [96], until prospective 
data are available, it is important to develop better 
sympto  matic management of these symptoms and to 
improve adherence in women receiving endocrine 
treatment.
Management
No large study has focused on the optimal management 
of AI-induced arthralgia (Table 3). Th  e majority of 
patients in the ATAC retrospective analysis had received 
some kind of treatment for their joint symptoms that 
consisted typically of non-steroidal anti-inﬂ  ammatory 
drugs and/or other analgesics [58]. Other reports have 
also described successful treatment of a subset of patients 
with analgesics, including non-steroidal anti-inﬂ  amma-
tory drugs, acetaminophen, and opioids [54,55,91,97]. 
Low dose corticosteroids were reported to be eﬀ  ective in 
one study, but the toxicity proﬁ   le and long-term side 
eﬀ   ects of corticosteroids make them an unappealing 
choice for treatment of AI-induced arthralgia [91].
Dietary supplementation with vitamins, glucosamine 
and chondroitin, omega ﬁ   sh oils, and Chinese herbal 
remedies have shown variable eﬃ   cacy [54,63]. A small 
study evaluated the eﬀ   ect of vitamin D and calcium 
supplementation started at the outset of AI therapy [98]. 
Although it was not a randomized placebo-controlled 
study, the authors showed that maintaining vitamin D 
levels >66 ng/ml resulted in lower rates of joint disability. 
Similarly, in a prospective cohort study [99], vitamin D 
Table 3. Treatment strategies for aromatase inhibitor-
associated musculoskeletal symptoms
Analgesics
 Acetaminophen
 NSAIDS
 COX2-specifi   c  agents
 Opioids
Other prescription medications
 Bisphosphonates
 Diuretics
 Antidepressants
 Anti-convulsants
Dietary supplements
 Calcium/vitamin  D
  Omega fi  sh oil
 Glucosamine/chondroitin
Non-pharmacologic approaches
 Acupuncture
 Exercise
 Yoga
 Massage
Other
 Drug  holiday
  Switching hormone therapy (to another AI or tamoxifen)
AI, aromatase inhibitor; COX, cyclo-oxygenase; NSAID, non-steroidal anti-
infl  ammatory drug.
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development of joint pain, although the authors found 
that despite supplementation many women on the study 
did not achieve adequate vitamin D levels. A larger 
prospective randomized placebo-controlled trial to 
evalu  ate vitamin D supplementation in AI-induced 
arthralgia is ongoing (NCT00263185). Bisphosphonates 
were identiﬁ  ed in a retrospective study as an inverse risk 
factor for developing AI musculoskeletal symptoms 
[100]; however, this has not been evaluated in a pros-
pective randomized placebo-controlled trial. Diuretics 
were recently reported to reduce arthralgia symptoms in 
a retrospective study consistent with the ﬁ  nding of joint 
eﬀ  usion and ﬂ  uid in the tendon sheaths [90]. Duloxetine, 
a serotonin and norepinephrine reuptake inhibitor, was 
shown to signiﬁ   cantly reduce AI-associated pain in a 
single-arm, open-label phase II study and improved 
functional status [101]. Other antidepressants and anti-
convulsants are often used in the treatment of chronic 
pain disorders; however, their use has not been evaluated 
in AI-induced arthralgia.
Acupuncture has been shown to be a feasible and 
eﬀ  ective treatment modality for AI-associated arthralgia 
[102]. In a randomized, single-blinded sham-controlled 
acupuncture trial, women treated with true acupuncture 
reported a two-point improvement in pain score com-
pared to women treated with sham acupuncture (80% 
versus 22%) [103]. Both these studies suggest non-
pharma  ceutical approaches may be beneﬁ  cial for women 
with AI-induced arthralgia and enhance adherence. 
Other non-pharmaceutical approaches, such as exercise, 
yoga, and massage, may also be beneﬁ  cial but have not 
been evaluated.
Th  e  eﬀ   ect of switching aromatase inhibitors on 
musculoskeletal symptoms was recently evaluated in the 
Articular Tolerance of Letrozole (ATOLL) study, a 
6-month, prospective, non-randomized, multicenter trial 
[104]. Patients who discontinued anastrozole because of 
musculoskeletal symptoms were started on letrozole and 
assessed for recurrence of symptoms, severity, and 
discontinuation of therapy. At the end of 6 months after 
switching from anastrozole to letrozole, 71.5% of patients 
continued therapy with letrozole while 28.5% discon-
tinued therapy secondary to severe joint pain. Although 
the joint symptoms were more tolerable and did not 
result in as many discontinuations, the majority of 
patients continued to have joint symptoms despite 
switching therapy. However, this study suggests that 
patients who are intolerant to one AI may beneﬁ  t from 
switching to another AI to continue to receive the 
beneﬁ   ts of the hormonal adjuvant therapy. Whether 
switching classes of AI (from steroidal to non-steroidal or 
vice versa) will be associated with improvement of 
symptoms has not been reported. Other reasonable 
alternatives include a drug holiday and/or switching to 
tamoxifen if clinically appropriate.
Conclusion
AIs are widely used in the treatment of early-stage breast 
cancer. While results from the deﬁ   nitive phase III 
randomized clinical trials comparing AI use to tamoxifen 
initially suggested that AI may result in a reduced toxicity 
proﬁ   le compared to tamoxifen, patient-reported out-
comes in prospective studies demonstrate that the 
musculo  skeletal side eﬀ   ects of these agents are sub-
stantial, increasing treatment-related morbidity and 
result  ing in treatment discontinuation. Given the signiﬁ  -
cantly increased risk of osteoporosis and fractures 
associated with AIs, a thorough assessment of risk factors 
prior to the start of therapy is indicated with considera-
tion to initiating preventative measures (calcium, vitamin 
D, bisphosphonates as indicated) at the outset of 
treatment.
In our practice, we encourage all women on AIs to 
participate in weight bearing exercise and take calcium 
and vitamin D supplements, and generally follow the 
United States Preventative Task Force guidelines for 
initiation of bisphosphonate therapy if osteoporosis is 
present on DEXA scan [105]. No guidelines are available 
for the treatment of AI-associated arthralgia. We 
approach treating these patients on a case-by-case basis, 
reserving discontinuation of therapy or switching to 
tamoxifen for refractory cases [2]. In our experience, 
there is a wide variability in response to non-steroidal 
anti-inﬂ  ammatory drugs, but newer approaches, includ-
ing non-pharmacologic treatments, hold promise for 
improving the tolerability of AIs.
Musculoskeletal symptoms in women treated with AIs 
represent a signiﬁ   cant burden whose etiology is still 
unexplained. Th   ere is a need to identify the mechanisms 
underlying the development of toxicity with a focus on 
determining predictive factors and prospective assess-
ment of interventional approaches. Eﬀ  ective management 
and symptomatic treatment of these symptoms is 
imperative to enhance adherence to therapy, improve 
outcomes, and decrease breast cancer recurrences.
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